Parallax Volatility Advisers
PTGX icon

Parallax Volatility Advisers’s Protagonist Therapeutics PTGX Stock Holding History

Parallax Volatility Advisers’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19
Closed – – 3697
2018
Q3 		$0 Buy
+19
New +$164 ﹤0.01% 3353
2018
Q1 		– Sell
-1,428
Closed -$30K – 3771
2017
Q4 		$30K Buy
+1,428
New +$25.3K ﹤0.01% 3492

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Parallax Volatility Advisers's PTGX Position: Q4 2018 in Review

Parallax Volatility Advisers sold out of Protagonist Therapeutics (PTGX) in Q4 2018, closing a stake of 19 shares.

Parallax Volatility Advisers first reported a position in PTGX in Q4 2017 and held it in 2 quarters. The position peaked at $30K in Q4 2017. 66 funds tracked by Wall St. Rank hold PTGX as of Q4 2018.

  • Parallax Volatility Advisers reported no remaining Protagonist Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 19 Protagonist Therapeutics shares in Q4 2018.
  • Parallax Volatility Advisers first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 2 quarters.
  • Parallax Volatility Advisers's Protagonist Therapeutics position peaked at $30K in Q4 2017.
  • 66 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2018.

Based on Parallax Volatility Advisers's 13F filing for Q4 2018, filed 14 Feb 2019.